Contemporary transformations
Radical anti-prohibitionism
Ayahuasca-analogue culture developed as practical opposition to prohibition. Its central move was not a petition for one protected sacrament but the discovery that the controlled experiential principle could be reconstituted through many botanical routes. Cultivated rue, regional wattles, Mimosa, selected grasses, retained caapi, canonical leaves and isolated compounds formed a repertoire of substitutions. Print and digital circulation added a second redundancy: once pharmacological roles were public knowledge, seizure of a shipment, closure of a supplier or restriction of one species could redirect experimentation rather than end it (Ott, 1994; DeKorne, 1996; Söderberg, 2022).
This was radical anti-prohibitionism in two senses. It rejected criminal punishment as the organising response to self-directed alteration of consciousness, and it challenged the premise that access required prior authorisation from the state, medicine or a recognised church. Ott’s polemical language of an “Entheogenic Reformation” cast the analogue as a means of breaking clerical and pharmacological monopolies. McKenna’s archaic revival situated prohibition within a wider critique of managed consciousness, consumer culture and ecological alienation. DeKorne’s small-press practice supplied the reproducible, provisional and corrective archive through which those ideas could become material experiments (Ott, 1994; 1996; McKenna, 1991; Monteith, 2016).
Biological distribution frustrates a plant-by-plant model of control, but it does not make government borders obsolete in law or practice. States can control a molecule, preparation, extract, act of manufacture or intended use; policing can burden some communities more heavily than others; and unscheduled status can change. The analogue’s political achievement is better described as regulatory redundancy: prohibition faces multiple species, techniques and knowledge pathways rather than a single geographically bounded commodity (Tupper and Labate, 2012; Walsh, 2016).
Cognitive liberty and democratisation
Cognitive liberty joins freedom from non-consensual intervention with freedom to investigate, alter and direct one’s own consciousness. Boire’s formulation emerged amid late-1990s concern with psychopharmacology, surveillance and neurotechnology; psychedelic drug policy became one instance of a wider contest over mental self-determination (Boire, 2000; Walsh, 2016; González Romero, 2023). Analogue practice gives the positive liberty claim a material infrastructure: distributed plants, an intelligible combination principle, replicable first-person inquiry and a peer archive.
Democratisation here has several layers. Geographic democratisation reduces dependence on Amazonian travel and imported flora. Technical democratisation translates an apparently singular preparation into functional roles that can be investigated by non-specialists. Epistemic democratisation admits first-person report and community knowledge alongside institutional evidence. Political democratisation treats extraordinary consciousness as a capacity whose legitimate exercise need not be confined to patients, research participants or members of exempted religions.
Each layer has exclusions. Plant knowledge, secure space, time, health screening, disability access, legal counsel and the ability to absorb criminal risk are unequally distributed. Online openness can conceal expertise behind confident prose, while race and class shape who is read as an experimenter, a patient or an offender. Local sourcing may reduce a long-distance commodity chain or transfer pressure to a rare species and erase the Indigenous history from which the combination principle became known. An open pharmacological commons requires conservation, attribution, reciprocal benefit and accessible safety knowledge if “democratisation” is to describe more than dispersal.
Corporate psychedelic renaissance and medicalised access
The contemporary “psychedelic renaissance” converts selected compounds and experiences into medicines, therapy protocols, professional competencies and investment assets. This translation can produce controlled safety data, screening standards, adverse-event response, legal routes of access and public legitimacy. It also narrows the authorised purposes of altered consciousness toward diagnosable illness, measurable outcome and supervised treatment. A person becomes eligible as a patient, not as a citizen claiming cognitive liberty; the experience enters public life through efficacy rather than an independent right to consciousness (Noorani, 2020; Walsh, 2016).
Analogue history complicates corporate accounts of innovation. Decades of illicit or legally ambiguous user practice generated botanical leads, experiential reports, interaction warnings and practical knowledge before venture-backed development. Pharmaceutical firms can formalise parts of this dispersed knowledge as compounds, salts, delivery systems, protocols and patents. Söderberg describes this movement as the conversion of “outlaw user innovation” into protected commercial assets; Marks and Cohen identify risks to competition, access and Indigenous knowledge when weak prior-art records meet expansive psychedelic patenting (Söderberg, 2022; Marks and Cohen, 2022).
Medicalisation is a cultural framework, not the absence of one. Diagnosis, informed consent, therapist neutrality, psychometric scales, quiet rooms, playlists and integration appointments organise expectation and interpretation. This framework has developed expertise in screening and acute support, yet it can translate sacrament into active ingredient, teacher into drug effect, community obligation into treatment compliance and long-term practice into a limited course of sessions. Costly therapist time, restrictive trial criteria, insurance exclusions and proprietary formulations can make legal access narrower than the rhetoric of a renaissance suggests (Noorani, 2020; Langlitz, 2013).
The analogue critique is directed at exclusivity, not at all clinical knowledge. Research and professional care need not require a monopoly over legitimate use. A plural governance model could recognise medical treatment, religious exercise, community practice and non-commercial adult self-direction while imposing proportionate standards for consent, advertising, ecological sourcing and facilitator accountability.
Direct access and missing institutions
Removing professional and geographic gatekeepers does not supply the social capacities that make difficult experiences navigable. Analogue culture often circulates chemical concepts more readily than durable preparation, supervision and aftercare. A forum can identify an interaction or normalise a crisis; a charismatic facilitator can offer continuity or exploit dependence; a borrowed ceremonial form can stabilise attention or misrepresent its authority. The political value of access and the practical need for competent care occupy different axes.
Four infrastructures recur where decentralised practice becomes sustainable: preparation, including medication review, psychiatric and physical-health screening and explicit consent; experienced accompaniment, including boundaries, emergency planning and referral; interpretive plurality, allowing spiritual, psychological and uncertain accounts without compelled belief; and integration, including follow-up, peer support and recognition of adverse or destabilising outcomes. Their absence is a public-health and community-governance problem. Criminal prohibition can worsen it by driving practice underground, discouraging disclosure and making transparent training or quality control legally hazardous (Tupper, 2008; Perkins et al., 2021; Bouso et al., 2022).
Materialism, ontology and the freedom to interpret
McKenna’s and Ott’s anti-materialist arguments treated entheogenic prohibition as regulation of admissible reality. Experiences of plant intelligence, autonomous entities, sacred presence or transpersonal knowledge challenged institutions that recognised only intoxication, hallucination or symptom. In this analysis, criminalisation protected not only public order but an epistemic hierarchy: biochemical explanation could be official, while metaphysical interpretation was privatised, medicalised or denied (Ott, 1996; Monteith, 2016).
That argument is most precise when framed as a conflict over interpretive jurisdiction, not as proof that modern authorities share one materialist motive. A neurobiological description and a sacred interpretation can coexist, compete or remain unresolved. Cognitive liberty includes room to interpret an experience without state-mandated metaphysics, clinical coercion or pressure from a ceremonial leader. It also includes freedom from imposed psychoactive states and from compulsory spiritual explanation. The political claim is not that one ontology should replace another, but that no institution should secure exclusive custody of consciousness by defining in advance every legitimate meaning it may bear.
Contemporary research
| Study | What it adds | What it cannot establish |
|---|
| Mueller et al. (2025) | Thirty-one healthy men received intranasal DMT with buccal harmine; the combination extended effects into a 2–3-hour, controllable window and was tolerated in this setting. | Not evidence for efficacy, women or diverse clinical populations; not a test of plants, ceremony or ayahuasca equivalence. |
| Bonomo et al. (2025) | First published clinical pilot of purified oral formulations derived from two unnamed Australian Acacia species and P. harmala; nine experienced healthy volunteers, supported by a therapist dyad. | The species were reported only as Acacia A/B. The small open-label sample and expectancy prevent generalisation; one high-dose participant had transient suicidal ideation that resolved with therapist intervention. |
| Suay et al. (2025) | Controlled DMT–harmine work investigated changes in creative dynamics, widening the research focus beyond acute intensity alone. | Laboratory creativity measures do not validate claims of plant intelligence or therapeutic transformation. |
| Aicher et al. (2026) | In 28 healthy men, DMT–harmine reduced post-performance embarrassment and shame in a karaoke paradigm, suggesting a testable social-emotional after-effect. | A small healthy-male experiment is neither an antidepressant trial nor proof of durable social healing. |
| Stojanović et al. (2026) | A scoping review mapped 26 registered interventional trials of ayahuasca, DMT and DMT–harmine, showing rapid institutional expansion and heterogeneous routes and targets. | Trial registration is not positive evidence, and compound studies cannot stand in for whole-rite ethnopharmacology. |
Conservation and biological threat
Species, not genera
Acacia conservation
Some wattles are common or invasive; others have tiny ranges. Acacia courtii is nationally Vulnerable in Australia and was listed Endangered in New South Wales in 2026. It was not identified as a source in the 2025 clinical paper, which withheld its two species names (Australian Government, 2026; NSW TSSC, 2026; Bonomo et al., 2025).
Destructive plant parts
Mimosa and bark markets
Mimosa tenuiflora is globally assessed as Least Concern, but root-bark removal kills or damages individual plants. Conservation status does not measure local extraction pressure, provenance or the ethics of commodity chains (IUCN, 2021).
Abundance is not safety
Phalaris and Peganum
Reed canary grass and rue are invasive in parts of their introduced ranges, but variable toxic alkaloids, contaminated sites and misidentification remain concerns. An ecological weed is not automatically a responsible medicine (Gill et al., 2020).
Amazonian displacement
Caapi supply
Substitution may reduce demand for transported vine, yet it can also preserve “ayahuasca” branding while removing Indigenous cultivators from the value chain. Neither global endangerment nor sustainability should be asserted without local evidence.
Law and governance
| Jurisdiction | Current position and analogue-specific problem |
|---|
| International | DMT is in Schedule I of the 1971 Psychotropic Convention. The INCB has stated that plants themselves are not internationally scheduled in the same manner, but national control of preparations, extraction and possession varies (United Nations, 1971; INCB, 2012). |
| United States | DMT remains Schedule I under federal law. Case-specific religious protections for ayahuasca churches do not create a general exemption for analogues, home manufacture or secular cognitive-liberty claims (US Government, 2026). |
| United Kingdom | DMT is a Class A, Schedule 1 controlled drug; preparations intended to contain it carry severe legal risk. Plant status does not provide a dependable analogue loophole (UK Government, 2026). |
| Brazil | CONAD Resolution No. 1/2010 regulates religious ayahuasca use. Its framework does not automatically legalise juremahuasca, pharmahuasca or substitutions outside recognised ayahuasca practice (CONAD, 2010). |
| Australia | The 2025 Acacia pilot reports that DMT and harmala alkaloids were Schedule 9 substances available in that study only through research permits. Native-plant status is not general permission (Bonomo et al., 2025). |
Legal information changes and is not legal advice. The analogue complex is particularly exposed to uncertainty because plant, preparation, isolated compound, intention, extraction and religious context may be treated differently.
Patents: from prior art to proprietary route
The DMT–harmala principle is old knowledge and cannot plausibly be owned as a new discovery. Contemporary patents instead target salts, solubility, delivery routes, kits, devices and therapeutic use. WO2021259962A1, assigned to the University of Zurich, concerns DMT–harmine combinations and non-oral administration; WO2024023274A2, assigned to Reconnect Labs AG, concerns soluble harmine formulations; US11235110B1 claims a vaporisation delivery system for “ayahuasca-like” substances (University of Zurich, 2021; Reconnect Labs AG, 2024; Monster Color Carnival LLC, 2022).
ASYMMETRYIndigenous combination knowledge can be treated as unownable prior art while a salt, device, route or clinical claim becomes private property. The analogue sits at a sharp frontier between cognitive commons and pharmaceutical enclosure.
